Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of TAK-385 vs Leuprorelin in Endometriosis
NCT03931915Phase 3Completed
- Sponsor
- ASKA Pharmaceutical Holdings Co., Ltd.
- Start
- May 2019
- Primary completion
- Jun 2020
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tissue-plasminogen activator in endometriosis (2 arms), sponsored by ASKA Pharmaceutical Holdings Co., Ltd. Primary endpoint: Change of maximum Visual Analogue Scale (VAS) score for endometriosis associated pelvic pain. Started May 2019; status: completed.
02
Drugs
tissue-plasminogen activator
03
Conditions
endometriosis
Beyond the preview
Go deeper on NCT03931915.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03931915.